The focus of precision oncology over the last 25 years has been on targeting druggable oncogenes with gain-of-function genetic alterations (i.e., BCR-ABL and EGFR). However, most solid tumors do not carry these types of mutations, but instead alterations in undruggable oncogenes or loss-of-function mutations in tumor suppressors. Synthetic lethality is a concept in which the simultaneous targeting of two pathways results in cell death, whereas the targeting of either pathway alone does not...